查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
擬人化小鼠·老鼠模型的全球市場:各類型，各用途，各終端用戶，各地區 - 預測(～2028年)
市場調查報告書
商品編碼
1316324

擬人化小鼠·老鼠模型的全球市場:各類型，各用途，各終端用戶，各地區 - 預測(～2028年)

Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models, Rat Models), Application, End User & Region - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 206 Pages | 訂單完成後即時交付

價格
簡介目錄

全球人源化小鼠和大鼠模型市場規模將從 2023 年的 2.59 億美元增至 2028 年的 3.49 億美元，預計在 2023-2028 年預測期內復合年增長率為 6.2%。

由於 CRISPR 的經濟性和快速結果，預計 CRISPR 將獲得轉基因小鼠品系開發的巨大需求。CRISPR 已成為一種強大的基因編輯技術，可供市場參與者進行基因工程和開發高效的基因人源化小鼠模型。

2022 年，人性化鼠標模型細分市場收入佔有率最高。

按類型劃分，市場分為人源化小鼠模型和人源化大鼠模型。人性化鼠標模型將在 2022 年佔市場最高的收入佔有率。預計該細分市場在預測期內將以最高複合年增長率增長。對基於細胞的人源化小鼠模型的需求不斷增長，促進了這一領域的增長。這些模型具有廣泛的應用，包括潛在新藥的安全性和有效性分析，免疫腫瘤學、傳染病和移植物抗宿主病等領域的長期研究。

2022 年，免疫學和傳染病領域佔第二大市場佔有率。

按應用劃分，市場分為腫瘤學、免疫學和傳染病、神經科學、造血、毒理學和其他應用。按銷售額計算，免疫學和傳染病領域是第二大市場領域。小鼠模型用於免疫學和炎症研究，以幫助評估實驗結果的生理相關性。小鼠模型可以對免疫過程進行詳細研究，因為小鼠基因組可以在隨機或特定區域進行適當改變。

歐洲是第二大市場區域。

市場分為北美、歐洲、亞太地區、拉丁美洲、中東和非洲。對抗癌的日益關注是推動市場增長的主要因素。兩個著名的歐洲組織——Cancer Core Europe 和 EuroOPDX Consortium（由 18 個非營利癌症中心和大學組成）的成立就證明了這一點。

本報告提供全球擬人化小鼠·老鼠模型市場相關調查分析，提供市場動態，地區和市場區隔的分析，企業簡介等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 主要考察

  • 擬人化小鼠·老鼠模型市場概要
  • 亞太地區的擬人化小鼠·老鼠模型市場:各終端用戶，各國
  • 北美的細胞為基礎的擬人化小鼠模式市場:各類型

第5章 市場概要

  • 簡介
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • 法規分析
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 價格分析
  • 技術分析
  • 價值鏈分析
  • 生態系統分析
  • 波特的五力分析
  • 專利分析
  • 主要的會議與活動
  • 主要的相關利益者與購買標準

第6章 擬人化小鼠·老鼠模型市場:各類型

  • 簡介
  • 擬人化小鼠模式
    • 遺傳基因擬人化小鼠模式
    • 細胞為基礎的擬人化小鼠模式
  • 人體化老鼠模型

第7章 擬人化小鼠·老鼠模型市場:各用途

  • 簡介
  • 腫瘤學
  • 免疫學·感染疾病
  • 神經科學
  • 毒理學
  • 造血
  • 其他的用途

第8章 擬人化小鼠·老鼠模型市場:各終端用戶

  • 簡介
  • 製藥企業·生物科技企業
  • CRO·CDMO
  • 學術·研究機關

第9章 擬人化小鼠·老鼠模型市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 北美的不景氣的影響
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲
    • 歐洲的不景氣的影響
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 其他的亞太地區
    • 亞太地區的不景氣的影響
  • 南美
  • 中東·非洲

第10章 競爭情形

  • 概要
  • 主要企業採用的策略
  • 市場佔有率分析
  • 企業的評估矩陣
  • Start-Ups/中小企業導向的企業的評估矩陣
  • 擬人化小鼠·老鼠模型市場:企業的足跡分析
  • 競爭方案和趨勢

第11章 企業簡介

  • 主要企業
    • CHARLES RIVER LABORATORIES
    • THE JACKSON LABORATORY
    • INOTIV
    • TACONIC BIOSCIENCES, INC.
    • CROWN BIOSCIENCE
    • CHAMPIONS ONCOLOGY, INC.
    • HERA BIOLABS
    • GENOWAY
    • VITALSTAR BIOTECHNOLOGY
    • INGENIOUS TARGETING LABORATORY
    • TRANS GENIC
    • HARBOUR ANTIBODIES BV (A SUBSIDIARY OF HARBOUR BIOMED)
    • ONCODESIGN
    • PHARMATEST SERVICES
  • 其他的企業
    • OZGENE PTY LTD.
    • TRANSCURE BIOSERVICES
    • CYAGEN BIOSCIENCES
    • ARAGEN LIFE SCIENCES LTD. (FORMERLY GVK BIO)
    • BIOCYTOGEN
    • GEMPHARMATECH

第12章 附錄

簡介目錄
Product Code: BT 4938

The global humanized mouse and rat model market is projected to reach USD 349 million by 2028 from USD 259 million in 2023, at a CAGR of 6.2% during the forecast period of 2023 to 2028. CRISPR is set to gain significant demand to develop genetically modified mouse strains, attributive to affordability and faster outcomes associated with CRISPR. CRISPR has emerged as a potent gene editing technology for market players for genetic modification, developing a efficient genetic humanized mouse models.

Humanized mouse models segment accounted for the highest revenue share in the market in 2022.

Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. In 2022, humanized mouse models have garnered the highest share in terms of revenue in the market. This segment is also expected to grow with a fastest CAGR through the forecast period. Increase in demand for cell-based humanized mouse models has contributed to the segment's growth. These models are used for a wide range of applications, such as analyzing the safety and effectiveness of potential new drugs and in long-term studies in the fields of immuno-oncology, infectious diseases, and graft-versus-host disease.

The immunology & infectious diseases segment accounted for the second largest share of the market in 2022

Based on application, the humanized mouse and rat model market is segmented into oncology, immunology & infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The immunology & infectious diseases segment is the second largest segment in the market in terms of revenue. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. Mouse models allow suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes.

Europe is the second largest region in the humanized mouse and rat model market

The humanized mouse and rat model market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). A growing focus on combating cancer is a key factor driving market growth. This is evident with the formation of two prominent organizations in Europe-Cancer Core Europe and the EurOPDX Consortium (comprising 18 not-for-profit cancer centers and universities).

The primary interviews conducted for this report can be categorized as follows:

  • By Company- Tire 1-37%. Tire 2-23%, Tire 3-40%
  • By Designation: C Level Executives - 32%, Director level - 26%, and others-42%
  • By Region: North America -35%, Europe -25%, Asia-Pacific -20%, Latin America -12%, and Middle East and Africa - 8%

List of Companies Profiled in the Report

  • Charles River Laboratories (US)
  • THE JACKSON LABORATORY (JAX) (US)
  • Taconic Biosciences, Inc. (US)
  • Crown Biosciences (US)
  • Champions Oncology, Inc. (US)
  • Hera BioLabs (US)
  • genOway (France)
  • Inotiv (US)
  • Vitalstar Biotechnology (China)
  • Ingenious Targeting Laboratory (US)
  • TRANS GENIC (Japan)
  • Harbour Antibodies BV (Netherlands)
  • Oncodesign (France)
  • Pharmatest Services (Finland)
  • Ozgene Pty Ltd. (Australia)
  • TransCure bioServices (France)
  • Cyagen Biosciences (US)
  • Aragen Life Sciences Ltd. (India)
  • GemPharmatech (China)
  • Biocytogen (US)

Research Coverage:

This report provides a detailed picture of the humanized mouse and rat model market. It aims at estimating the size and future growth potential of the market across different segments such as the type, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall humanized mouse and rat model market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (Growth in the humanized mouse and rat model market is majorly driven by the rising use of humanized models in drug discovery research, rising demand for personalized medicine, government-funded initiatives for cancer research, increasing R&D activities in pharmaceutical & biotechnology industry), restraints (High cost of custom humanized models, and regulatory compliance for ethical use of animal mode are expected to restrain the growth of this market during the forecast period), opportunities (Growing demand for humanized mouse models, preference for humanized PDX models, and emergence of CRISPR in biomedical research), challenges (Limitations of humanized mouse models and alternative methods for animal testing) are influencing the growth of humanized mouse and rat model market.
  • Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the humanized mouse and rat model market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the humanized mouse and rat model market across varied regions.
  • Market Diversification: Exhaustive information about new product, untapped geographies, recent developments, and investments in the humanized mouse and rat model market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies product offerings of leading players like Charles River Laboratories (US), THE JACKSON LABORATORY (JAX) (US), Taconic Biosciences, Inc. (US), Inotiv (US), among others in the humanized mouse and rat model market. The report also helps stakeholders understand the pulse of humanized mouse and rat model market and provides them information on key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Breakdown of primary sources
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 PRIMARY INSIGHTS
  • 2.3 MARKET SIZE ESTIMATION
    • FIGURE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS)
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
  • 2.4 MARKET GROWTH RATE PROJECTIONS
    • FIGURE 5 HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS
    • FIGURE 6 HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 2.4.1 DATA TRIANGULATION AND MARKET BREAKDOWN
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK IMPACT ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024-2028 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 8 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 10 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 GEOGRAPHICAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL MARKET

4 PREMIUM INSIGHTS

  • 4.1 HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW
    • FIGURE 12 RISING USE OF HUMANIZED MODELS IN DRUG DISCOVERY RESEARCH TO DRIVE MARKET
  • 4.2 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER AND COUNTRY
    • FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA FOR 2022
  • 4.3 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE (USD MILLION)
    • FIGURE 14 PBMC HUMANIZED MOUSE MODELS SEGMENT TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 HUMANIZED MOUSE AND RAT MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising use of humanized models in drug discovery research
      • 5.2.1.2 Growing preference for personalized medicine
      • 5.2.1.3 Government-funded initiatives for cancer research
      • 5.2.1.4 Increasing R&D activities in pharmaceutical & biotechnology industries
    • TABLE 4 NUMBER OF R&D PRODUCTS, BY INDICATION (2022)
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of custom humanized models
      • 5.2.2.2 Stringent regulatory compliance for ethical use of animal models
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing preference for humanized PDX models
      • 5.2.3.2 Emergence of CRISPR in biomedical research
      • 5.2.3.3 Rising demand for humanized rat models
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Alternative methods for animal testing
      • 5.2.4.2 Limitations of humanized mouse models
  • 5.3 REGULATORY ANALYSIS
    • 5.3.1 NORTH AMERICA
    • 5.3.2 EUROPE
    • 5.3.3 ASIA PACIFIC
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
    • 5.3.4 LATIN AMERICA
    • 5.3.5 MIDDLE EAST & AFRICA
  • 5.4 PRICING ANALYSIS
    • TABLE 5 PRICE OF HUMANIZED MOUSE MODELS (2022)
  • 5.5 TECHNOLOGY ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 16 CREATION OF HUMANIZED MODELS-MAXIMUM VALUE IS ADDED DURING IMPLANTATION OF GRAFT/TUMOR CELLS IN IMMUNODEFICIENT MICE OR RATS
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 17 HUMANIZED MOUSE AND RAT MODEL MARKET: ECOSYSTEM MAP
    • TABLE 6 SUPPLY CHAIN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 7 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 PATENT ANALYSIS
  • 5.10 KEY CONFERENCES AND EVENTS
    • 5.10.1 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES AND EVENTS IN 2023
    • TABLE 8 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES AND EVENTS IN 2023
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 18 HUMANIZED MOUSE AND RAT MODEL MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
    • 5.11.2 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY BUYING CRITERIA
    • FIGURE 19 KEY BUYING CRITERIA FOR END USERS

6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 6.2 HUMANIZED MOUSE MODELS
    • TABLE 10 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 11 HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 12 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 13 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 14 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.1 GENETIC HUMANIZED MOUSE MODELS
      • 6.2.1.1 Advancements in genetic engineering technologies to drive market
    • TABLE 15 GENETIC HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 16 NORTH AMERICA: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 17 EUROPE: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 18 ASIA PACIFIC: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.2 CELL-BASED HUMANIZED MOUSE MODELS
    • TABLE 19 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 20 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 21 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.2.2.1 CD34 humanized mouse models
        • 6.2.2.1.1 Rising demand for stem cell therapy to propel market
    • TABLE 23 CD34 HUMANIZED MODELS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 24 NORTH AMERICA: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 25 EUROPE: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 ASIA PACIFIC: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.2.2.2 PBMC humanized mouse models
        • 6.2.2.2.1 Growing prevalence of infectious diseases to fuel uptake
    • TABLE 27 PBMC HUMANIZED MICE MODELS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 28 NORTH AMERICA: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 29 EUROPE: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 ASIA PACIFIC: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.2.2.3 BLT humanized mouse models
        • 6.2.2.3.1 Increasing HIV cases to propel market
    • TABLE 31 BLT HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 32 NORTH AMERICA: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 EUROPE: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 34 ASIA PACIFIC: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 HUMANIZED RAT MODELS
    • 6.3.1 ABILITY TO SUSTAIN HIGH INTRAVENOUS DOSING TO SUPPORT MARKET GROWTH
    • TABLE 35 HUMANIZED RAT MODELS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 36 NORTH AMERICA: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 EUROPE: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 ASIA PACIFIC: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 39 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 7.2 ONCOLOGY
    • 7.2.1 UTILIZATION OF MOUSE MODELS IN CANCER RESEARCH TO PROPEL MARKET
    • TABLE 40 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 41 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 IMMUNOLOGY AND INFECTIOUS DISEASES
    • 7.3.1 DEVELOPMENT OF ADVANCED MODELS FOR TREATMENT OF RARE DISEASES TO DRIVE MARKET
    • TABLE 44 HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 45 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 NEUROSCIENCE
    • 7.4.1 RISING INCIDENCE OF CNS DISORDERS TO PROPEL MARKET
    • TABLE 48 HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 49 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 50 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.5 TOXICOLOGY
    • 7.5.1 INCREASING CLINICAL TRIALS FOR TOXICOLOGY STUDIES TO SUPPORT MARKET GROWTH
    • TABLE 52 HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 53 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.6 HEMATOPOIESIS
    • 7.6.1 RISING DEMAND FOR STEM CELL THERAPY TO DRIVE MARKET
    • TABLE 56 HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 57 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 58 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.7 OTHER APPLICATIONS
    • TABLE 60 HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 62 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 64 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 8.2.1 INCREASING EXPENDITURE ON R&D FOR DRUG DEVELOPMENT TO DRIVE MARKET
    • TABLE 65 HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 66 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 67 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS
    • 8.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES BY PHARMA & BIOTECH COMPANIES TO PROPEL MARKET
    • TABLE 69 HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 70 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 71 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 72 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 ACADEMIC & RESEARCH INSTITUTES
    • 8.4.1 SUPPORTIVE FUNDING INVESTMENTS FOR LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH
    • TABLE 73 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 74 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 75 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 76 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)

9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 77 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 20 HUMANIZED MOUSE AND RAT MODEL MARKET: NORTH AMERICA SNAPSHOT
    • TABLE 78 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 79 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 80 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 81 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 82 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 83 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 Growing research initiatives on mAbs and biosimilars to drive market
    • TABLE 84 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 85 US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 86 US: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 87 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 88 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Government initiatives on stem cell research to drive market
    • TABLE 89 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 90 CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 91 CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 92 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 93 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.2.3 NORTH AMERICA: RECESSION IMPACT
  • 9.3 EUROPE
    • TABLE 94 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 95 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 96 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 97 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 98 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 99 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Rising pharmaceutical R&D expenditure to drive market
    • TABLE 100 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 101 GERMANY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 102 GERMANY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 103 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 104 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 Growing investments in cancer research to drive market
    • TABLE 105 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 106 UK: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 107 UK: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 108 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 109 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Increasing initiatives for genomics research to support market growth
    • TABLE 110 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 111 FRANCE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 112 FRANCE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 113 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 114 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 Rising R&D spending on pharmaceutical production to fuel market
    • TABLE 115 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 116 ITALY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 117 ITALY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 118 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 119 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Rising growth in biotech industry to drive market
    • TABLE 120 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 121 SPAIN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 122 SPAIN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 123 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 124 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 125 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 126 REST OF EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 127 REST OF EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 128 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 129 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.3.7 EUROPE: RECESSION IMPACT
  • 9.4 ASIA PACIFIC
    • FIGURE 21 HUMANIZED MOUSE AND RAT MODEL MARKET: ASIA PACIFIC SNAPSHOT
    • TABLE 130 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 131 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 132 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 133 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 134 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 135 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.1 CHINA
      • 9.4.1.1 High growth in pharmaceutical industry to drive market
    • TABLE 136 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 137 CHINA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 138 CHINA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 139 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 140 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.2 JAPAN
      • 9.4.2.1 Growing research collaborations among pharmaceutical companies to drive market
    • TABLE 141 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 142 JAPAN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 143 JAPAN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 144 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 145 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Growth in biotech industry to drive market
    • TABLE 146 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 147 INDIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 148 INDIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 149 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 150 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.4 SOUTH KOREA
      • 9.4.4.1 Rising government-funded investments for pharmaceutical R&D to drive market
    • TABLE 151 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 152 SOUTH KOREA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 153 SOUTH KOREA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 154 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 155 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.5 REST OF ASIA PACIFIC
    • TABLE 156 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 157 REST OF ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 158 REST OF ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 159 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 160 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.4.6 ASIA PACIFIC: RECESSION IMPACT
  • 9.5 LATIN AMERICA
    • 9.5.1 GROWING PRESENCE OF PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO PROPEL MARKET
    • TABLE 161 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 162 LATIN AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 163 LATIN AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 164 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 165 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.5.2 LATIN AMERICA: RECESSION IMPACT
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 RISING INITIATIVES FOR CLINICAL TESTING TO SUPPORT MARKET GROWTH
    • TABLE 166 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 167 MIDDLE EAST & AFRICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 168 MIDDLE EAST & AFRICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 169 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 170 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 22 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY STRATEGIES ADOPTED BY MARKET PLAYERS (2019-2023)
  • 10.3 MARKET SHARE ANALYSIS
    • FIGURE 23 HUMANIZED MOUSE AND RAT MODEL MARKET SHARE FOR KEY PLAYERS (2022)
    • TABLE 171 HUMANIZED MOUSE AND RAT MODEL MARKET: INTENSITY OF COMPETITIVE RIVALRY
  • 10.4 COMPANY EVALUATION MATRIX
    • 10.4.1 STARS
    • 10.4.2 EMERGING LEADERS
    • 10.4.3 PERVASIVE PLAYERS
    • 10.4.4 PARTICIPANTS
    • FIGURE 24 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX OF LEADING PLAYERS (2022)
  • 10.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES
    • 10.5.1 PROGRESSIVE COMPANIES
    • 10.5.2 STARTING BLOCKS
    • 10.5.3 RESPONSIVE COMPANIES
    • 10.5.4 DYNAMIC COMPANIES
  • 10.6 HUMANIZED MOUSE AND RAT MODEL MARKET: FOOTPRINT ANALYSIS OF COMPANIES
    • TABLE 172 HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT FOOTPRINT ANALYSIS (2022)
    • TABLE 173 HUMANIZED MOUSE AND RAT MODEL MARKET: END-USER FOOTPRINT ANALYSIS
    • TABLE 174 HUMANIZED MOUSE AND RAT MODEL MARKET: REGIONAL FOOTPRINT ANALYSIS (2022)
  • 10.7 COMPETITIVE SCENARIO AND TRENDS
    • TABLE 175 HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT LAUNCHES
    • TABLE 176 HUMANIZED MOUSE AND RAT MODEL MARKET: DEALS

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 11.1.1 CHARLES RIVER LABORATORIES
    • TABLE 177 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 26 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)
    • 11.1.2 THE JACKSON LABORATORY
    • TABLE 178 THE JACKSON LABORATORY: BUSINESS OVERVIEW
    • FIGURE 27 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2022)
    • 11.1.3 INOTIV
    • TABLE 179 INOTIV: COMPANY OVERVIEW
    • FIGURE 28 INOTIV: COMPANY SNAPSHOT
    • 11.1.4 TACONIC BIOSCIENCES, INC.
    • TABLE 180 TACONIC BIOSCIENCES, INC.: BUSINESS OVERVIEW
    • 11.1.5 CROWN BIOSCIENCE
    • TABLE 181 CROWN BIOSCIENCE: BUSINESS OVERVIEW
    • 11.1.6 CHAMPIONS ONCOLOGY, INC.
    • TABLE 182 CHAMPIONS ONCOLOGY, INC.: BUSINESS OVERVIEW
    • FIGURE 29 CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT (2022)
    • 11.1.7 HERA BIOLABS
    • TABLE 183 HERA BIOLABS: BUSINESS OVERVIEW
    • 11.1.8 GENOWAY
    • TABLE 184 GENOWAY: BUSINESS OVERVIEW
    • 11.1.9 VITALSTAR BIOTECHNOLOGY
    • TABLE 185 VITALSTAR BIOTECHNOLOGY: BUSINESS OVERVIEW
    • 11.1.10 INGENIOUS TARGETING LABORATORY
    • TABLE 186 INGENIOUS TARGETING LABORATORY: BUSINESS OVERVIEW
    • 11.1.11 TRANS GENIC
    • TABLE 187 TRANS GENIC: BUSINESS OVERVIEW
    • FIGURE 30 TRANS GENIC: COMPANY SNAPSHOT
    • 11.1.12 HARBOUR ANTIBODIES BV (A SUBSIDIARY OF HARBOUR BIOMED)
    • TABLE 188 HARBOUR ANTIBODIES BV: BUSINESS OVERVIEW
    • FIGURE 31 HARBOUR BIOMED: COMPANY SNAPSHOT
    • 11.1.13 ONCODESIGN
    • TABLE 189 ONCODESIGN: BUSINESS OVERVIEW
    • 11.1.14 PHARMATEST SERVICES
    • TABLE 190 PHARMATEST SERVICES: BUSINESS OVERVIEW
  • 11.2 OTHER PLAYERS
    • 11.2.1 OZGENE PTY LTD.
    • 11.2.2 TRANSCURE BIOSERVICES
    • 11.2.3 CYAGEN BIOSCIENCES
    • 11.2.4 ARAGEN LIFE SCIENCES LTD. (FORMERLY GVK BIO)
    • 11.2.5 BIOCYTOGEN
    • 11.2.6 GEMPHARMATECH
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS